Facts and controversies in systemic treatment of metastatic breast cancer

Oncologist

Volumn 9, Issue 6, 2004, Pages 617-632

  Bernard Marty, Chantal ^a   Cardoso, Fatima ^a   Piccart, Martine J ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Biological therapy; Breast cancer; Chemotherapy; Endocrine therapy; Tailoring therapy

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; CAPECITABINE; CARBOPLATIN; DAUNORUBICIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; EXEMESTANE; FADROZOLE; FORMESTANE; GEMCITABINE; HORMONE RECEPTOR; LETROZOLE; MEGESTROL ACETATE; NAVELBINE; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; VOROZOLE;

ADVANCED CANCER; ANOREXIA; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DRUG ERUPTION; DRUG POTENCY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; MEDICAL DECISION MAKING; MONOTHERAPY; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SWEATING; THROMBOEMBOLISM; TREATMENT FAILURE; TREATMENT PLANNING; WEIGHT GAIN;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; NEOPLASM METASTASIS; PREMENOPAUSE; RECEPTOR, ERBB-2;

EID: 9144268610     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.9-6-617     Document Type: Review

References (141)

1. Greenberg P, Hortobágyi G, Smith T et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:2197-2205.
2. Hortobágyi GN, Piccart-Gebhart MJ. Current management of advanced breast cancer. Semin Oncol 1996;23(suppl 11):1-5.
3. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
4. Girard P, Baldeyrou P, le Chevalier T et al. Surgery for pulmonary metastases. Who are the 10-year survivors? Cancer 1994;74:2791-2797.
5. McKenna RJ Jr, McMurtrey MJ, Larson DL et al. A perspective on chest wall resection in patients with breast cancer. Ann Thorac Surg 1984;38:482-487.
6. Temple WJ, Ketcham AS. Surgical management of isolated systemic metastases. Semin Oncol 1980;7:468-480.
7. Systematic reviews in health care. Meta-analysis in context. In: Egger M, Davey Smith G, Altman DG, eds. Systematic Reviews, 2nd ed. London: BMJ Books, 2001.
8. Holmes FA, Buzdar AU, Kau SW et al. Combined-modality approach for patients with isolated recurrences of breast cancer (IV-NED). The M.D. Anderson experience. Breast Disease 1994;7:7-20.
9. Rivera E, Holmes FA, Buzdar AU et al. Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer who have no evidence of disease. Breast J 2002;8:2-9.
10. Nieto Y, Nawaz S, Jones RB et al. Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol 2002;20:707-718.
11. Glass EL, Heffelfinger S, Blau R et al. Estrogen receptor and progesterone receptor status: differences between primary and metastatic breast cancer. Breast Cancer Res Treat 2003;82(suppl 1):257a.
12. Smith IE, Harris AL, Morgan M et al. Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. BMJ 1981;283:1432-1434.
13. Johnston SRD, Smith IE, Dowsett M et al. Place of aromatase inhibitors in the endocrine therapy of breast cancer. In: Miller WR, Santen RJ, eds. Aromatase Inhibition and Breast Cancer. New York: Marcel Dekker, 2001:29-49.
14. Buzdar AU, Jones SE, Vogel CL et al. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Cancer 1997;15:730-739.
15. Jonat W, Howell A, Blomqvist C et al. A randomised trial comparing two doses of the new selective aromatase inhibitor Anastrozole ('Arimidex') with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 1996;32A:404-412.
16. Buzdar A, Jonat W, Howell A et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol 1996;14:2000-2011.
17. Buzdar AU, Jonat W, Howell A et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998;83:1142-1152.
18. Bergh J, Bonneterre J, Illiger HJ et al. Vorozole (Rivizor) versus aminoglutethimide (AG) in the treatment of postmenopausal breast cancer relapsing after tamoxifen. Proc Am Soc Clin Oncol 1997;16:543.
19. Dombernowsky P, Smith I, Falkson G et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998;16:453-461.
20. Gershanovich M, Chaudri HA, Campos D et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (ARIBC3). Ann Oncol 1998;9:639-645.
21. Goss PE, Winer EP, Tannock IF et al. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor Vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. J Clin Oncol 1999;17:52-63.
22. Kaufmann M, Bajetta E, Dirix LY et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000;18:1399-1411.
23. Nabholtz JM, Buzdar A, Pollak M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18:3758-3767.
24. Bonneterre J, Thurlimann B, Robertson JF et al. Anastrozole versus tamoxifen as first line treatment for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or Arimidex randomized Group Efficacy and Tolerability Study. J Clin Oncol 2000;18:3748-3757.
25. Bonneterre J, Buzdar A, Nabholtz JM et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Results of two randomized trials designed for combined analysis. Cancer 2001;92:2247-2258.
26. Mouridsen H, Gershanovich M, Sun Y et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101-2109.
27. Paridaens R, Dirix L, Lohrisch C et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003;14:1391-1398.
28. Howell A, Robertson JFR, Quaresma Albano J et al. Fulvestrant, formerly ICI 182,780 is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20:3396-3403.
29. Osborne CK, Pippen J, Jones SE et al. Double-blind randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002;20:3386-3395.
30. Robertson JFR, Howell A, Abram P et al. Fulvestrant versus tamoxifen for the first-line treatment of advanced breast cancer (ABC) in postmenopausal women. Ann Oncol 2002;13:1640.
31. Vergote I, Robertson JF, Kleeberg U et al. Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy. Breast Cancer Res Treat 2003;79:207-211.
32. Thurlimann B, Robertson JF, Nabholtz JM et al. Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer 2003;39:2310-2317.
33. Dowsett M, Stein RC, Coombes RC. Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients. J Steroid Biochem Mol Biol 1992;43:155-159.
34. Celio L, Martinetti A, Ferrari L et al. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study. Anticancer Res 1999;19:2261-2268.
35. Dowsett M, Doody D, Miall S et al. Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer. Breast Cancer Res Treat 1999;56:25-34.
36. Forward DP, Cheung KL, Jackson L et al. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 2004;90:590-594.
37. Pritchard KI, Thomson DB, Myers RE et al. Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat Rep 1980;64:787-796.
38. Sawka CA, Pritchard KI, Shelley WE et al. A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: a report of the National Cancer Institute of Canada Trials Group (NCIC CTG) trial MA.1. Breast Cancer Res 1997;44:211-215.
39. Ingle JN, Krook JE, Green SJ et al. Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 1986;4:178-185.
40. Buchanan RB, Blamey RW, Durrant KR et al. A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with metastatic breast cancer. J Clin Oncol 1986;4:1326-1330.
41. Crump M, Sawka CA, DeBoer G et al. An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer. Breast Cancer Res 1997;44:201-210.
42. Taylor CW, Green S, Dalton WS et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor positive metastatic breast cancer: an intergroup study. J Clin Oncol 1998;16:994-999.
43. Klijn J, Blamey R, Boccardo F et al. A new standard treatment for advanced premenopausal breast cancer: a meta-analysis of the Combined Hormonal Agent Trialists' group (CHAT). Eur J Cancer 1998;345:405.
44. Nicholson RI, McClelland RA, Robertson JFR et al. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 1999;6:373-387.
45. Eiermann W, Paepke S, Appffelstaedt J et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomised double-blind multicenter study. Ann Oncol 2001;12:1527-1532.
46. Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808-3816.
47. Dowsett M, Smith I. Greater Ki67 response after 2 weeks neoadjuvant treatment with anastrozole (A) versus tamoxifen (T) or anastrozole plus tamoxifen (C) in the IMPACT trial: a potential predictor of relapse-free survival. Br Cancer Res Treat 2003;82(suppl 1):S6.
48. Henderson IC. Chemotherapy for metastatic disease. In: Harris JR, Hellman S, Henderson IC et al., eds. Breast Diseases. Philadelphia: J.B. Lippincott Company, 1991:604-665.
49. Ellis MJ, Hayes DF, Lippman ME. Treatment of metastatic breast cancer. In: Harris JR, Lippman ME, Morrow M et al., eds. Diseases of the Breast. Philadelphia: Lippincott Williams & Wilkins, 2000:749.
50. Hortobágyi GN. Treatment of breast cancer. N Engl J Med 1998;339:974-984.
51. Cardoso F, Di Leo A, Lohrisch C et al. Second and subsequent lines of chemotherapy for metastatic breast cancer: What did we learn in the last two decades? Ann Oncol 2002;13:197-207.
52. O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:2812-2823.
53. Fossati R, Confalonieri C, Torri V et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomised trials involving 31,150 women. J Clin Oncol 1998;16:3439-3460.
54. Chlebowski RT, Smalley RV, Weiner JM et al. Combination versus sequential single agent chemotherapy in advanced breast cancer: association with metastatic sites and long-term survival. The Western Cancer Study Group and the Southeastern Cancer Study Group. Br J Cancer 1989;59:227-230.
55. Joensuu H, Holli K, Heikkinen M et al. Combination chemotherapy versus single agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial. J Clin Oncol 1998;16:3720-3730.
56. Nabholtz JM, Senn HJ, Bezwoda WR et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999;17:1413-1424.
57. Bishop JF, Dewar J, Toner GC et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 1999;17:2355-2364.
58. Norris B, Pritchard KI, James K et al. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol 2000;18:2385-2394.
59. Heidemann E, Stoeger H, Souchon R et al. Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. Ann Oncol 2002;13:1717-1729.
60. Sledge GW, Neuberg D, Ingle J et al. Phase III trial of doxorubicin, paclitaxel and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer (MBC): an Intergroup trial (E1193). J Clin Oncol 2003;21:588-592.
61. A'Hern RP, Smith IE, Ebbs SR. Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. Br J Cancer 1993;67:801-805.
62. Findlay BP, Walker-Dilks C. Epirubicin, alone or in combination chemotherapy, for metastatic breast cancer. Provincial Breast Cancer Disease Site Group and the Provincial Systemic Treatment Disease Site Group. Cancer Prev Control 1998;2:140-146.
63. French Epirubicin Study Group. A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. J Clin Oncol 1991;9:305-312.
64. French Epirubicin Study Group. Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment. J Clin Oncol 2000;18:3115-3124.
65. Bernard-Marty C, Cardoso F, Piccart MJ. Use and abuse of taxanes in the management of metastatic breast cancer. Eur J Cancer 2003;39:1978-1989.
66. Sjöström J, Blomqvist C, Mouridsen H et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999;35:1194-1201.
67. Bonneterre J, Roche H, Monnier A et al. Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 2002;87:1210-1215.
68. O'Shaughnessy J, Nag S, Calderillo-Ruiz G et al. Gemcitabine plus paclitaxel versus paclitaxel as first-line treatment for anthracycline pre-treated metastatic breast cancer: interim results of a global phase III study. Proc Am Soc Clin Oncol 2003;22:7.
69. Chan S, Friedrichs K, Noel D et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999;17:2341-2354.
70. Paridaens R, Biganzoli L, Bruning P et al. Paclitaxel versus doxorubicin as first line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer randomized study with cross-over. J Clin Oncol 2000;18:724-733.
71. Nabholtz JM, Falkson C, Campos D et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003;21:968-975.
72. Nabholtz JMA, Paterson A, Dirix L et al. A phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) (TAC) to FAC as first line chemotherapy (CT) for patients with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2001;20:22a.
73. Mackey JR, Paterson A, Dirix LY et al. Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2002;21:35a.
74. Bontenbal M, Braun JJ, Creemers GJ et al. Phase III study comparing AT (adriamycin, docetaxel) to FAC (fluorouracil, adriamycin, cyclophosphamide) as first-line chemotherapy (CT) in patients with metastatic breast cancer (MBC). Eur J Cancer Suppl 2003;1:S202.
75. Jassem J, Pienkowski T, Pluzanska A et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first line therapy for women with metastatic breast cancer: Final results of a randomized phase III multicenter trial. J Clin Oncol 2001;19:1707-1715.
76. Biganzoli L, Cufer T, Bruning R et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of cancer 10961 multicenter phase III trial. J Clin Oncol 2002;20:3114-3121.
77. Luck H, Thomssen C, Untch M et al. Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC). Epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC). A study of the AGO Breast Cancer Group. Proc Am Soc Clin Oncol 2000;19:73a.
78. Carmichael J. UKCCCR Trial of epirubicin and cyclophosphamide (EC) versus epirubicin and Taxol® (ET) in the first line treatment of women with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2001;20:22a.
79. Ravdin P, Erban J, Overmoyer B et al. Phase III comparison of docetaxel (D) and paclitaxel (P) in patients with metastatic breast cancer (MBC). Eur J Cancer Suppl 2003;1:S201.
80. Mamounas E, Brown A, Smith R et al. Effect of Taxol duration of infusion in advanced breast cancer (ABC): results from NSABP B-26 trial comparing 3- to 24-hour infusion of high-dose Taxol. Proc Am Soc Clin Oncol 1998;17:101a.
81. Holmes FA, Valero V, Buzdar AU et al. Final results: randomized phase III trial of paclitaxel by 3-hour versus 96-hour infusion in patients with metastatic breast cancer. The long & short of it. Proc Am Soc Clin Oncol 1998;17:110a.
82. Perez EA. Paclitaxel in breast cancer. The Oncologist 1998;3:373-389.
83. Marchetti P, Urien S, Cappellini GA et al. Weekly administration of paclitaxel: theoretical and clinical basis. Crit Rev Oncol Hematol 2002;44(suppl):S3-S13.
84. Buzdar AU, Singletary SE, Theriault RL et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 1999;17:3412-3417.
85. Burris HA III, Yardley D, Jones S et al. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol 2004;22:1621-1629.
86. Valero V, Jones SE, Von Hoff DD et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 1998;16:3362-3368.
87. Ishitobi M, Shin E, Kikkawa N. Metastatic breast cancer with resistance to both anthracycline and docetaxel successfully treated with weekly paclitaxel. Int J Clin Oncol 2001;6:55-58.
88. Roche HH, Cure H, Bunnell C et al. A phase II study of epothilone analog BMS-247550 in patients (pts) with metastatic breast cancer (MBC) previously treated with an anthracycline. Proc Am Soc Clin Oncol 2003;22:18.
89. D'Incalci M, Schüller J, Colombo T et al. Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations. Semin Oncol 1998;25(suppl 13):16-20.
90. Schüller J, Czejka M, Krexner E et al. Pharmacokinetic (PK) interaction of the combination of doxorubicin (DOX) and Taxotere (TXT). Ann Oncol 1998;9:126.
91. Gianni L, Viganò L, Locatelli A et al. Different interference of paclitaxel (PTX) on human pharmacokinetics of doxorubicin (DOX) and epirubicin (EPI). Proc Am Soc Clin Oncol 1997;16:224a.
92. Blum JL, Jones SE, Buzdar AU et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-493.
93. Talbot DC, Moiseyenko V, Van Belle S et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002;86:1367-1372.
94. O'Shaughnessy JA, Blum J, Moiseyenko V et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) versus a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001;12:1247-1254.
95. O'Shaughnessy J, Blum J. A retrospective evaluation of the impact of dose reduction in patients treated with Xeloda (capecitabine). Proc Am Soc Clin Oncol 2000;19:400.
96. Michaud LB, Gauthier MA, Wojdylo JR et al. Improved therapeutic index with lower dose capecitabine in metastatic breast cancer patients. Proc Am Soc Clin Oncol 2000;19:402.
97. Canobbio L, Boccardo F, Pastorino G et al. Phase II study of navelbine in advanced breast cancer. Semin Oncol 1989;16(suppl 4):33-36.
98. Degardin M, Bonneterre J, Hecquet B et al. Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 1994;5:423-426.
99. Freyer G, Delozier T, Lichinister M et al. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 2003;21:35-40.
100. Zielinski C, Beslija S, Mrsic-Krmpotic Z et al. Gemcitabine/epirubicin/ paclitaxel vs 5-fluorouracil/epirubicin/cyclophosphamide as first-line treatment in metastatic breast cancer: demographics of a randomized, multicenter phase III trial of the Central European Cooperative Oncology Group. Proc Am Soc Clin Oncol 2003;22:7.
101. Clark GM. Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status? J Natl Cancer Inst 1998;90:1320-1321.
102. Paik S, Bryant J, Park C et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998;90:1361-1370.
103. Thor AD, Berry DA, Budman DR et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998;90:1346-1360.
104. Di Leo A, Cardoso F, Scohy S et al. Predictive molecular markers: a new window of opportunity in the adjuvant therapy of breast cancer. In: Naboltz JM, Tonkin K, Reese DM et al., eds. Breast Cancer Management - Application of Clinical and Translational Evidence to Patient Care, 2nd ed. United Kingdom: Lippincott Williams & Wilkins, 2003;367-380.
105. Di Leo A, Isola J. Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning? Clin Breast Cancer 2003;4:179-186.
106. Jarvinen TA, Tanner M, Barlund M et al. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 1999;26:142-150.
107. Withoff S, Keith WN, Knol AJ et al. Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel. Br J Cancer 1996;74:502-507.
108. Kandioler-Eckersberger D, Taucher S, Steiner B et al. P53 genotype and major response to anthracycline or paclitaxel based neoadjuvant treatment in breast cancer patients. Proc Am Soc Clin Oncol 1998;17:102a.
109. Bernard-Marty C, Treilleux I, Dumontet C et al. Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. Clin Breast Cancer 2002;3:341-345.
110. Lenz HJ, Leichman CG, Danenberg KD et al. Thymidylate synthase m RNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 1995;14:176-182.
111. Fox SB, Engels K, Comley M et al. Relationship of elevated tumor thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF. Ann Oncol 1997;8:271-275.
112. Hurwitz H, Fehrenbacher L, Cartwright T et al. Bevacizumab (Avastin, a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc Am Soc Clin Oncol 2003;22:3646.
113. Burnstein HJ, Parker LM, Savoie J et al. Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer. Breast Cancer Res Treat 2002;76(suppl 1):S115.
114. Baselga J, Albanell J, Ruiz A et al. Phase II and tumor pharmacodynamic study of gefinitib (ZD1839) in patients with advanced breast cancer. Proc Am Soc Clin Oncol 2003;22:7.
115. Robertson JFR, Gutteridge E, Cheung KL et al. Gefinitib is active in acquired tamoxifen (TAM)-resistant estrogen receptor (ER)-positive and ER-negative breast cancer: results from a phase II study. Proc Am Soc Clin Oncol 2003;22:7.
116. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-2648.
117. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726.
118. Extra JM, Cognetti F, Chan S et al. First-line trastuzumab (Herceptin,) plus docetaxel versus docetaxel alone in women with HER2-positive metastatic breast cancer (MBC): results from a randomised phase II trial (M77001). Br Cancer Res Treat 2003;82(suppl 1):S47.
119. Paik S, Bryant J, Tan-Chiu E et al. Real-world performance of HER-2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94:852-854.
120. Roche PC, Suman VJ, Jenkins RB et al. Concordance between local and central laboratory HER-2 testing in the Breast Intergroup Trial N9831. J Natl Cancer Inst 2002;94:855-857.
121. Dowsett M, Bartlett J, Ellis IO et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 2003;199:418-423.
122. Leyland-Jones B, Arnold A, Gelmon K et al. A pharmacokinetic (PK) study of Herceptin® administered with paclitaxel i.v. every 3 weeks. Eur J Cancer 2000;36(suppl 5):S53.
123. Leyland-Jones B, Hemmings F, Arnold A et al. Pharmacokinetics of Herceptin administered with Paclitaxel every three weeks. Br Cancer Res Treat 2000;64:124.
124. Gelmon K, Arnold A, Verma S et al. Pharmacokinetics (PK) and safety of trastuzumab (Herceptin) when administered every three weeks to women with metastatic breast cancer. Proc Am Soc Clin Oncol 2001;20:271.
125. Pietras, RJ, Pegram MD, Finn RS et al. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998;17:2235-2249.
126. Tripathy D, Slamon D, Cobleigh M et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004;22:1063-1070.
127. Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer 2002;95:1592-1600.
128. Cardoso F, Piccart MJ, Durbecq V et al. Resistance to trastuzumab: a necessary evil or a temporary challenge? Clin Breast Cancer 2002;3:247-257; discussion 258-259.
129. Sørlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-8423.
130. Sotiriou C, Neo SY, McShane LM et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003;100:10393-10398.
131. Marty M, Baselga J, Gatzemeier U et al. Changes in left ventricular ejection fraction (LVEF) during trastuzumab therapy: a pooled analysis of four trials. Proc Am Soc Clin Oncol 2003;22.
132. Burris HA 3rd. Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin). Semin Oncol 2000;27(suppl 3):19-23.
133. Esteva FJ, Valero V, Booser D et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:1800-1808.
134. Jahanzeb M, Mortimer JE, Yunus F et al. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer. The Oncologist 2002;7:410-417.
135. Burstein HJ, Harris LN, Marcom PK et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003;21:2889-2895.
136. O'Shaughnessy J, Vukelja SJ, Marsland T et al. Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results. Clin Breast Cancer 2002;3(suppl 1):17-20.
137. Bangemann N, Kuhle A, Willrodt RG et al. Treatment of HER2 overexpressing metastatic breast cancer (MBC) with trastuzumab (Herceptin) and chemotherapy. Br Cancer Res Treat 2002;64:123.
138. Robert N, Leyland-Jones B, Asmar L et al. Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with Her2/neu positive advanced breast cancer. Breast Cancer Res Treat 2002;76(suppl 1):S37.
139. Rowland KM, Suman VJ, Ingle JN et al. NCCTG 98-32-52: randomized phase II trial of weekly versus every 3-week administration of paclitaxel, carboplatin and trastuzumab in women with HER2 positive metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2003;22:8.
140. Atalay G, Cardoso F, Awada A et al. Novel therapeutic strategies targeting the EGFR (epidermal growth factor receptor) family and its downstream effectors in breast cancer. Ann Oncol 2003;14:1346-1363.
141. Gee JM, Harper ME, Hutcheson IR et al. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 2003;144:5105-5117.